Summary.-A soft-agar diffusion-chamber technique was used to grow colonies from human melanoma xenografts. Plating efficiencies ranged from 0.042o% to 750, and increased with serial passage of some tumours. Cells in colonies were similar to human melanoma cells in morphology, histochemistry and ultrastructure, and were shown by immunofluorescence to contain human antigens. Xenograft tumours could be regrown from the colonies when re-implanted into immune-deprived mice.
human melanoma cells in morphology, histochemistry and ultrastructure, and were shown by immunofluorescence to contain human antigens. Xenograft tumours could be regrown from the colonies when re-implanted into immune-deprived mice.
Cell-survival curves were constructed from 5 xenograft lines treated with 4 cytotoxic drugs. All lines were resistant to adriamycin, but each line appeared to have an individual spectrum of sensitivity to the more effective drugs. The responses were compatible with the clinical pattern of response in melanoma, and in 2 cases the objective response of lung metastases to treatment with melphalan was consistent with the xenograft cell-survival data. Dose-response curves were exponential for treatment with methyl-CCNU and melphalan, but distinct plateaux were seen for 2 xenografts treated with doses of DTIC over 100 mg/kg. These were thought to be due to resistant subpopulations of clonogenic cells within the tumours.
THE VALUE of human xenografts in therapeutic cancer research will depend upon two main factors: on the clear demonstration that xenografts retain the biological and therapeutic response characteristics of the source tumours, and upon the availability of methods by which tumour response can reliably be quantified. Most investigations have so far involved the measurement of the volume response to therapy of xenografts, especially the degree of tumour growth delay. Such measurements are particularly vulnerable to host rejection mechanisms .
The measurement of the survival of colony-forming cells after treatment is an alternative endpoint of tumour response, which has been widely applied to experimental and animal tumours. (1lonogenic cell-survival studies have been reported for pancreatic and colonic carcinoma xenografts treated with cyclophosphamide and xenografts of various histological types treated with radiation Guichard et al., 1977 . In the present work we have sought to study further the applicability of clonogenic cell survival studies to human tumour xenografts, to confirm that colonies originate from human tumour cells, and to assess the clinical impact of the results. A series of human tumour xenografts was established in immune-deprived mice and compared with their source tumours (Selby et al., 1.980) . Five xenografts of a single histological type (melanoma) were then the subject of detailed cell-survival studies, using a range of clinically relevant chemotherapeutic agents. Steel et al. (1978) . Xenografting mnethods and studies of the tumours have been described previously . The present studies were performed before the 5th passage of all tumours, except HX34, which was studied in the 12th-17th passages as well as in the first 4 passages from frozen material. Colony growth and characterization.-Tumour pieces were taken aseptically from 1cm. diameter xenografts and washed in phosphate-buffered saline. They were minced with crossed scalpels, taken up into Ham's F12 medium with 20% Special Bobby Calf Serum (Gibco) and shaken firmly to free single cells. Enzymatic digestion was not used. The cell suspensions were then washed in medium with serum and filtered through a 20,um nylon mesh. The entire procedure was carried out under sterile conditions in a laminar downfloN cabinet. Cell suspensions were counted in a haemacytometer under a phase-contrast microscope after adding lissamine green. Bright cells which excluded the dye were regarded as viable. Colonies were grown in soft agar in diffusion chambers incubated in the peritoneal cavities of preirradiated mice according to the method of Smith et al. (1976) .
For studies of colony cell morphology, the chambers containing colonies in agar were fixed in Bouin's solution for 24 h and the agar transferred to 700% ethanol. The fixed agar was paraffin-embedded and sections were cut and stained. For enzyme histochemistry, it proved possible to freeze the semi-solid agar and cut frozen sections on a standard cryostat. Sections were stained with haematoxylin and eosin, and also the Fontana silverimpregnationi technique for melanin. Histochemical techniques for localization of the enzymes dopa-oxidase and non-specific esterase were also used. For electroni microscopy, 1-2mm cubes of agar containing colonies were fixed and examined by standard inethods. Human antigens were identified in colonies by a simple immunofluorescence technique pieviously described Drugs.-The drugs selected for this study were dacarbazine (DTIC, Dome Laboratories) and methyl-CCNU (NCJ), chosen because they are widely recognized as being among the more efficacious available for the treatment of malignant melanoma (Constanza et. al., 1977) ; melphalan (Alkeran, Wellcome) because it is now being investigated extensively at this hospital in high-dose treatment of metastatic melanoma (McElwain et al., 1979) ; and adriamycin (Pharmitalia) because this widely used drug has been ineffective against malignant melanoma and serves as a negative control (Sieper et al., 1975) . Methyl-CCNU wNas dissolved in dimethylsulphoxide and diluted in 5% Tween-80 detergent (BDH Chemicals) in saline. The other drugs were prepared according to manufacturers' instructions, and all wvere used immediately after preparation.
RESULTS
Colony growth was studied in cell suspensions prepared from the 10 human melanoma xenografts using the agar diffusion-chamber technique. Five of these tumour lines were treated with drugs and clonogenic cell survival was measured.
Colony growth
Plating efficiency.-The PEs for the melanoma xenografts are shown in Table I .
Colonies grew from all xenografts tested, with PE ranging from 0-042 to 7500. All except HX45 gave PE > 100 and HX34, 41 and 47 consistently gave PE > 10%. Table I for PE refer to values obtained with red blood cells when they led to an increase, or without if they did not.
Colony morphology and histology. Colonies varied among xenografts in density, regularity of outline and degree of cell packing. They were essentially compact, but for some tumours individual cells could be distinguished at the edges, whilst for others this was not possible. Histological sections showed the colonies to be compatible with the tumour of origin in cell morphology and pigmentation. Large compact colonies were shown to have necrotic centres. Dopa-oxidase, an enzyme specific to the melanin biosynthetic pathway, was demonstrated in frozen sections of colonies from HX41. Non-specific esterase, specific for mononuclear phagocytic cells, was not demonstrated in any of the compact colonies studied. Under electron microscopy, colonies from HX41 consisted of cells similar in ultrastructure to those seen in the xenografted tumour ( Fig. 1) . Numerous melanin granules and melanosomes, with their characteristic internal structure, were seen. The melanin content of colony cells appeared to be more uniform than in the xenograft -)Jo* 6-5 (6-0-7-1) 7-0 (5 6-9 2) 20 8 (12-2-70.1) 4-8 (4-1-5-8) 6-2 (5.7-6.7)t 4-4 (3 8-5 2) 10-2 (7-:3-17) poorly (lefine(d 15-7 (11 0-27 4) 8 9 (6-:3-14 8) Fig. 5 shows cell-survival data for all 5 xenografts treated with adriamycin. In no case was survival below 0 5.
The effect of modifying the time of assay after drug administration was studied in HX34 for all 4 drugs. In no case was there a significant change in cell survival when assay was delayed from 3 to 18 h. This study was not designed to seek correlation between cell-survival curves of individual melanomas as xenografts and the response of the same tumour to treatment in the patient. However, 2 patients whose tumours were studied as xenografts were treated with melphalan and comparison of their responses is possible. Fig. 6 shows the volume of lung metastases estimated from chest radiographs in these 2 patients after i.v. treatment with melphalan at 140 mg/M2. The patient from whom xenograft HX47 originated had a substantial response to this treatment, with marked reduction in the volume of one lung metastasis and disappearance of another. Unfortunately, this response in the patient was transient; the metastases regrew quickly and the patient died with overwhelming disease. The xenografts from this patient ranked second in response to melphalan (Table II) with a survival at the LD,o of < 1%.
The patient from whom HX41 originated was treated with a similar dose of melphalan, with very little effect on the measurable lung metastases or his cutaneous and hepatic metastases. This patient died with extensive disease 3 weeks after treatment. The tumour as a xenograft was also less sensitive than HX47 and the surviving fraction of clonogenic cells was > 10% at the LD10.
In separate experiments, the results of which are not shown, the serum levels of melphalan, measured by mass spectroscopy by Dr M. Jarman of this Institute or using radio-labelled melphalan, have been shown to be similar in mice receiving an LD10 dose and in patients receiving 140 mg/M2 i.v.
DISCUSSION

Colony growth
The direct evidence that colonies scored in the present study were derived from human tumour cells was strong. They were compatible with the tumour-of-origin in cell morphology, karyotype, ultrastructure, pigment content and enzyme content, and they contained human antigens demonstrated by immune fluorescence. In the case of HX34 and 41, the re-implantation of colonies into immunosuppressed mice produced tumours resembling uncloned xenografts. It seems likely that the "diffuse" colonies were derived from mouse cells of the macrophage series, as found by Stephens et al. (1978) . They were morphologically suggestive of mononuclear phagocytes, were probably positive for non-specific esterase and did not bear human antigens demonstrable by immunofluorescence. Although in the present work it seemed simple to distinguish tumour-cell from non-tumour-cell colonies when scoring the chambers, there clearly is a potential pitfall here in cell survival and cloning studies on xenografts.
The quoted plating efficiencies (Table I) were determined as the ratio of colonies scored to the number of viable cells plated, the latter being counted on a haemacytometer, using size and morphology to distinguish tumour and stromal cells. This distinction is unlikely to be absolute, and it is thus possible that some non-malignant cells were counted and included in the denominator of the ratio. 
Clonogentc cell survival
This is the first study in which it has been possible to measure cell survival after therapy of a range of human tumour xenografts of a single histological type. Cell survival provides an important alternative to tumour growth delay or tumour cure for assessing the response to treatment of tumours including xenografts, and provides a measure of cell kill that is uncorn-plicated by the effects of host response upon the tuimours. In addition to the present study of humaan melanoma xenografts, the success of cloning colonic, oatcell, uterine and ovarian carcinomas in diffusion chambers (Smith et al., 1976, 1978, and unpublished observations) The observation of exponential cellsurvival curves for melphalan and MeCCNU is in keeping with published work oni animal tumours (Valeriote & Tolen, 1972; Hill & Stanley, 1975) and in in vitro cell lines (Barlogie & Drewinko, 1977; Barranco et al., 1978) . This result supports the hypothesis that greater therapeutic effect against a tumour may be anticipated when higher doses of these agents are used in man, providing that increased toxicity to the patient cani be circumvented or effectively treated (McElwain et al., 1979) .
The finding of plateaux in the doseresponse curves of HX34 and HC47 to DTIC was surprising, however. We are unaware of evidence that the pharmacology of DTIC leads to a limitation or saturation of the drug effect at high doses, or that it has cycle-specificity (Symposium on DTIC, 1976) . Cycle specificity is unlikely to be the explanation for the plateaus, because they occurred below 1 0-2 cell survival, and a time-survival study showed that this level was reached within 3 h. It Sieper et al., 1975) . MeCCNU and DTIC were effective against some tumours, but not all, which is observed in clinical practice (Constanza et al., 1977) . Melphalan was moderately effective against 4 of the melanomas when given in maximum tolerated doses, in keeping with the results from high doses of melphalan to treat patients with metastatic melanoma. A substantial proportion of such patients achieve partial remissions and a few tumours regress completely (McElwain et al., 1979) . The two direct comparisons between the cell-survival curves of the melanoma xenografts and the clinical response of the donor patients are encouraging. This adds to the growing body of evidence that the chemosensitivity of individual human tumours is retained in their xenografts (Nowak et al., 1978; Giovanella et al., 1978; Shorthouse et al., 1980) and suggests that the use of this precise, quantifiable endpoint will prove valuable in further studies of this question.
